United Therapeutics Corp (UTHR) is now in the Overvalued zone, suggesting that its current forward PE ratio of 17.48 is considered Overvalued compared with the five-year average of 12.33. The fair price of United Therapeutics Corp (UTHR) is between 360.59 to 452.26 according to relative valuation method. Compared to the current price of 509.94 USD , United Therapeutics Corp By Overvalued By 12.75%.

Relative Value

Fair Zone

360.59-452.26

Current Price：509.94

12.75%

Overvalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is United Therapeutics Corp (UTHR) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

United Therapeutics Corp (UTHR) has a current Price-to-Book (P/B) ratio of 3.23. Compared to its 3-year average P/B ratio of 2.26, the current P/B ratio is approximately 42.95% higher. Relative to its 5-year average P/B ratio of 2.30, the current P/B ratio is about 40.58% higher. United Therapeutics Corp (UTHR) has a Forward Free Cash Flow (FCF) yield of approximately 5.25%. Compared to its 3-year average FCF yield of 6.55%, the current FCF yield is approximately -19.95% lower. Relative to its 5-year average FCF yield of 6.48%, the current FCF yield is about -19.02% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for UTHR competitors is 6.73, providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR.O) exhibits a P/S ratio of 6.38, which is -5.22% above the industry average. Given its robust revenue growth of 7.38%, this premium appears unsustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of UTHR increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of UTHR in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is UTHR currently overvalued or undervalued?

United Therapeutics Corp (UTHR) is now in the Overvalued zone, suggesting that its current forward PE ratio of 17.48 is considered Overvalued compared with the five-year average of 12.33. The fair price of United Therapeutics Corp (UTHR) is between 360.59 to 452.26 according to relative valuation method. Compared to the current price of 509.94 USD, United Therapeutics Corp is Overvalued By 12.75%.

What is United Therapeutics Corp (UTHR) fair value?

UTHR's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of United Therapeutics Corp (UTHR) is between 360.59 to 452.26 according to relative valuation method.

How does UTHR's valuation metrics compare to the industry average?

The average P/S ratio for UTHR's competitors is 6.73, providing a benchmark for relative valuation. United Therapeutics Corp Corp (UTHR) exhibits a P/S ratio of 6.38, which is -5.22% above the industry average. Given its robust revenue growth of 7.38%, this premium appears unsustainable.

What is the current P/B ratio for United Therapeutics Corp (UTHR) as of Mar 02 2026?

As of Mar 02 2026, United Therapeutics Corp (UTHR) has a P/B ratio of 3.23. This indicates that the market values UTHR at 3.23 times its book value.

What is the current FCF Yield for United Therapeutics Corp (UTHR) as of Mar 02 2026?

As of Mar 02 2026, United Therapeutics Corp (UTHR) has a FCF Yield of 5.25%. This means that for every dollar of United Therapeutics Corp's market capitalization, the company generates 5.25 cents in free cash flow.

What is the current Forward P/E ratio for United Therapeutics Corp (UTHR) as of Mar 02 2026?

As of Mar 02 2026, United Therapeutics Corp (UTHR) has a Forward P/E ratio of 17.48. This means the market is willing to pay $17.48 for every dollar of United Therapeutics Corp's expected earnings over the next 12 months.

What is the current Forward P/S ratio for United Therapeutics Corp (UTHR) as of Mar 02 2026?

As of Mar 02 2026, United Therapeutics Corp (UTHR) has a Forward P/S ratio of 6.38. This means the market is valuing UTHR at $6.38 for every dollar of expected revenue over the next 12 months.

UTHR Valuation